Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESP Block vs PIF Block vs Control for Sternotomy
NCT04985500Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jul 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (3 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Opioid Consumption at 72 hours. Started Jul 2021; status: active, not recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04985500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985500.